![]() FDA authorized emergency use of the company’s point-of-care System, which rapidly detects certain Coronavirus antibodies from a fingerstick sample.Ĭoronavirus Testing Stocks Vs. Quest has been scaling up capacity and indicated that it would be able to perform ~150k coronavirus antibody tests per day by early-May, using tests from Abbott and Euroimmun.Ĭhembio Diagnostics (240% YTD Return, $0.3 billion market cap): The small-cap company has seen its stock rally by over 240% year-to-date, as it made steady progress with coronavirus related diagnostics. diagnostics chains - has been impacted by the pandemic and associated shutdowns, as diagnostic testing for other conditions has been interrupted, the company is likely to benefit from stronger demand for COVID tests. ![]() Quest Diagnostics (1% YTD Return, $14 billion market cap): While Quest - one of the largest U.S. Below, we take a look at the key products offered by companies in this space and how testing stocks could stack up versus potential therapeutics and vaccine stocks. listed companies with exposure to coronavirus testing, view our indicated list of Coronavirus testing stocks. For more details on the stock price and fundamental performance of some of the key U.S. The S&P 500, on the other hand, is down 12% year-to-date. While the stock price of Abbott labs has gained 9% year-to-date as of 24th April, with Quest Diagnostics up by 1%, smaller-cap stocks in the diagnostics space such as Co-Diagnostics and Chembio are up 15x and 2.5x respectively. Demand for coronavirus test kits has also significantly outstripped supply thus far, and the stocks of companies providing testing equipment and services have generally outperformed the broader index. government on Monday indicated that it would scale up its testing strategy significantly, providing enough tests for all 50 states to screen at least 2% of their populations. Testing is viewed as key to containing the spread of the Coronavirus pandemic and re-opening the economy until a safe vaccine is developed. An Overview of Coronavirus Testing Stocks View our interactive dashboard analysis Is Quest Diagnostics Expensive Or Cheap Compared To LabCorp? for a detailed comparison of the fundamentals of the two companies and their stock price returns. While this could be partly due to Quest’s moves to quickly scale up COVID testing capacity, the company has also posted stronger EPS growth over the past few years, while holding a slightly smaller debt load compared to LabCorp. Quest stock has outperformed, rising by about 4% year-to-date, compared to LabCorp stock which is down by about 3%.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |